Latest News
2010-08-30
Meda to acquire Alaven
Meda has signed an agreement to acquire the US specialty pharmaceutical company Alaven. Meda will pay 350 MUSD on a cash and debt free basis. Net debt is estimated to 63 MUSD. The acquisition is expected to be completed by early October. The agreement will enhance Meda’s marketing capabilities in the US. It will also expand the company’s therapeutic focus to include both gastroenterology and women’s health.
>> Read more
2010-08-26
Fresenius Medical Care acquires Gambro’s peritoneal dialysis business
Fresenius Medical Care has signed an agreement to acquire Gambro’s worldwide peritoneal dialysis business. Gambro will prioritize its investments in the hemodialysis field. The acquisition is an opportunity for Fresenius Medical Care to expand its activities in the homecare market, in particular in Europe and Asia-Pacific.
>> Read more
2010-08-17
Becton Dickinson shuts down plant in Sweden
The US medical supply manufacturer Becton Dickinson has given notice to all 393 employees at its plant in Gåsebäck, Helsingborg in Sweden. The lay offs are to begin in February 2011 and production will cease before the end of 2011.
>> Read more
2010-08-12
XANO sells Inmedic
XANO Industri has signed an agreement for the sale of all shares in Inmedic AB with subsidiaries to Hammarplast Medical AB. Inmedic supplies advanced manufacturing services to the medical technology industry and has been part of XANO’s business unit Plastic Components. Production is carried out in Sweden and Estonia and takes place entirely in classified clean room environments.
>> Read more
2010-08-10
NsGene and Biogen Idec sign new agreement
NsGene and Biogen Idec have signed a new commercialization and license agreement on Neublastin, a novel therapeutic protein in clinical development for neuropathic pain. The expanded agreement grants Biogen Idec exclusive global rights to commercialize Neublastin for all indications, and in all formulations.
>> Read more
2010-07-02
Genmab and GSK announce amendment to ofatumumab agreement
The two companies have announced an amendment to the ofatumumab co-development and commercialization agreement. In the agreement, GlaxoSmithKline (GSK) will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.
>> Read more
2010-06-28
EpiCept signs agreement for purchase of 6.1M shares of common stock
The company has entered a definitive agreement for the purchase of approximately 6.1 million shares of its common stock $1.10 per share, five year warrants to purchase up to around 4.6 million shares of common stock at an exercise price of $1.57 per share exercisable beginning December 30 2010 and one year warrants to purchase up to approximately 6.1 million shares of common stock at an exercise price of $1.57 per share exercisable beginning December 30, 2010.
>> Read more
2010-06-23
Medivir and GSK enters exclusive agreement
Medivir and GlaxoSmithKline (GSK) have announced an exclusive agreement for the commercialization of Medivir’s cold sore treatment Xerclear (acyclovir and hydrocortisone). The agreement concerns non-prescription use (OTC) in key global markets.
>> Read more
John Clarke, President Consumer Healthcare at GSK
2010-06-23
Santaris Pharma and miRagen collaborates
The two companies have announced collaboration regarding development of microRNA-targeted medicines for cardiovascular diseases. Santaris Pharma is a Danish clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. miRagen Therapeutics is a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease.
>> Read more
Santaris Pharma headquarter, Hoersholm, Denmark
2010-06-22
Diamyd Medical signs breakthrough agreement
Swedish biotech company Diamyd Medical, developing diabetes therapies, has signed a license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson (J&J) company. The agreement includes world-wide commercialization and continued development of its GAD65 antigen-based therapy for the treatment of type 1 diabetes. Johnson & Johnson will pay an upfront fee of USD 45 million to Diamyd and additional milestone payments of up to USD 580 million may be paid out under the terms of the agreement.
>> Read more
2010-06-09
AstraZeneca to slash 280 jobs in Södertälje
As part of their package of global cutbacks 280 Research Fellows posts will be dismissed from the
AstraZeneca unit in Södertälje, Sweden. Of the 280 alerts 170 are researchers from Pharmaceutical Development Unit and a further 110 are working in clinical trials.
>> Read more
2010-06-14
Exclusive agreement between Nanexa and Neoventa Medical
The nanotechnology company Nanexa and the Medtech company Neoventa have signed an agreement to develop and use Nanexa’s technology within the perinatal care area. In the first application Neoventa and Nanexa will develop a sensor that measures lactate during labour and delivery. Lactate is an indicator for oxygen depletion of the fetus.
>> Read more
Back to top
More entries..
